Dr. Bikash Ranjan Jena, M.Pharm., Ph.D

@cutm.irins.org

ASSOCIATE PROFESSOR IN PHARMACEUTICAL ANALYSIS RESEARCH DIVISION
Centurion University of Technology and Management, Bhubaneswar, Odisha, INDIA

Dr. Bikash Ranjan Jena, M.Pharm., Ph.D


                           Download Compact PDF  
https://researchid.co/bikysims2020
Introduction: Dr. Bikash R Jena rurrently working at the Department of Pharmaceutical Analysis & Research Division at Centurion University (UGC, NAAC A+ accredited multi-sector skill university), Bhubaneswar Campus, Odisha, India. He has earned his Ph.D in Pharmaceutical Analysis at KL Deemed to be University (KLEF), UGC, NAAC A++ accredited, NIRF Rank 22, Category 1 University, Vadeswaram, Vijayawada, A.P., India.
Currently pursuing ADDRA from Jamia Hamdard, Deemed to be University, New Delhi (A Govt. Aided Deemed University, NIRF 1st 2025, UGC, NAAC A+ accredited), India.
So far I have 14+ years of academic & research experience in pharmaceutical analysis, chemometrics (AQbD), and bioanalytical development. I have published more than 88+ papers (research/review), Edited 5 international textbooks. Published 3 books as editor/co-editor & published 45+ book chapters in UGC-recognized, peer-reviewed impact journals (indexed in Scopus/Web of Sci/SCIE/PubMed) of reputed publishers

EDUCATION

Ph.D Awarded, at KL Deemed to be University, (UGC, NAAC A++, NIRF 22, Category 1 University), Vijayawada, A.P, India, Having 14 Yrs of academic and research experience. Published more than 50+ research Publications
Working as a Ph.D. research scholar and actively involved in Analytical Development. Assay, RS, Method Development, Method Validations, stability studies of novel compounds, using some sophisticated analytical instruments.
Persuing ADDRA at renowned Jamia Hamdard, Deemed to be University, New Delhi (A Govt. Aided Deemed University, NIRF 40, UGC, NAAC A+ accredited), India.

RESEARCH INTERESTS

Biotechnology, Chemistry, Medical Microbiology, Oncology, Statistics

Additional Specialties: I am very much interested for scientific writing, DoE avenue by using AQBD approach, Medical Writing, Publishing scientific manuscripts related to pharmaceutical (Analytical Research) fields with high indexing national and international journals.
58

Scopus Publications

469

Scholar Citations

12

Scholar h-index

13

Scholar i10-index

Scopus Publications

  • Physiologically Based Pharmacokinetic Modeling of Regorafenib Monohydrate-Loaded PEGylated PLGA Nanoparticles Employing GastroPlus™ Software
    Dhananjay Panigrahi, Surya Kanta Swain, Bikash Ranjan Jena, Pratap Kumar Sahu
    International Journal of Advancement in Life Sciences Research, 2026
    Nanoparticles (NPs) have transformed drug delivery by altering the pharmacokinetics of small-molecule therapeutics by dramatically enhancing solubility, bioavailability and tumour specificity. By leveraging the enhanced permeability and retention EPR effect characteristics of tumour vasculature, nanoparticles exhibit preferential localisation within neoplastic tissues, enabling deep intratumoral penetration and the targeted delivery of therapeutic agents with high spatial precision. When wrapped in hydrophilic polymers like polyethylene glycol (PEG), these smart carriers evade immune detection, extending systemic circulation and amplifying drug accumulation at the disease site. Yet the very properties that make NPs so effective, such as their tunable size, shape, surface charge, and chemistry, also render their in vivo behaviour highly complex and difficult to predict from traditional in vitro assays. To bridge this gap, advanced modelling methodologiessuch as physiologically based pharmacokinetic modelling offer robust avenues for predicting the outcome, efficacy, and safety of these nanoengineered therapies. In these research findings, a robust rabbit physiologically based pharmacokinetic model or toxicokinetic model.
  • Quality by Design Optimization of Telmisartan-loaded Self-nanoemulsifying Drug Delivery Systems
    Rajib Lochan Maharana, Suryakanta Swain, Santosh Kumar Mahapatra, Bikash Ranjan Jena
    Current Nanomedicine, 2026
    Aim: This study aimed to develop a QbD-based SNEDDS for Telmisartan to enhance its biopharmaceutical performance. Background: Quality by Design (QbD) was incorporated by selecting the Critical Process Pa-rameters (CPPs) as influential variables upon the desired responses. Using Design of Experiments (DoE) software, oil, and S/CoS were tested for pre-isotropic compatibility and formulation im-provement. A heating-cooling cycle and phase separation were used to determine the formula-tions' dispersibility, self-emulsifying time, mean globule size, and stability. Objective: Using Design of Experiments (DoE) software, oil (Capmul MCM C-10) and surfactant (Labrasol)/co-surfactant (Tween-20, and PEG-600) (S/CoS) ratios were optimized for pre-isotropic compatibility and formulation improvement. Methods: Aerosil-200, Sylysia-350, 550, and 730 were used as porous carriers, and Neusilin US2 as an adsorbing agent resulted in free-flowing granules of self-nano emulsifying drug delivery systems. The SNEDDS was further formulated into tablets using a direct compression technique with enhanced disintegration properties. Results: The prepared SNEDDS tablets exhibited a 71% increase in drug dissolution as compared to the pure drug and marketed formulation after the in vitro dissolution studies. Conclusion: This QbD approach offers a promising strategy for developing SNEDDS formula-tions for poorly soluble drugs like Telmisartan.
  • Topical nanoparticles for the treatment of skin cancer: Present concerns and challenges
    Pritipragatika Nayak, Surya Kanta Swain, Itishree Jogamaya Das, Sushree Sambita Swain, Bikash Ranjan Jena, et al.
    Journal of Drug Delivery Science and Technology, 2025
  • Quality By Design Enabled Carvedilol Self-Nanoemulsifying Drug Delivery System: In Vitro and In Vivo Characterization for Improved Management of Hypertension
    Rajib Lochan Maharana, Surya Kanta Swain, Santosh Kumar Mahapatra, Debashish Ghose, Bikash Ranjan Jena, et al.
    Biomedical Sciences and Clinical Medicine, 2025
    OBJECTIVE Due to poor absorption and substantial hepatic first-pass metabolism, carvedilol, a commonly used cardiovascular drug for hypertension and congestive heart failure, has a low and variable bioavailability. In order to enhance carvedilol solubility and prevent the first-pass impact, the current research work intends to produce SNEDDS of the drug using systematic DoE. This will ultimately increase its bioavailability. METHODS: By choosing the critical process parameters as factors that influenced the intended responses, quality by design was made possible. Oil and S/CoS were examined for pre-isotropic compatibility and formu-lation enhancement using Design of Experiment software. The cumulative percentage of drug release (QT30) in minutes, emulsification time (ET) in minutes, and emulsion globule size (nm) of the nano formulations were measured using a heating-cooling cycle and phase separation. To enhance carvedilol biopharmaceutical efficacy and oral bioavailability for the therapeutic management of cardiovascular disease. The carvedilol loaded self-nano emulsifying drug delivery system has been prepared by admixture method with selected oil, surfactant, and co-surfactant based on higher mean saturation solubility of drug. QbD approach presents an effective method to develop SNEDDS formulations of carvedilol with enhanced Using Design of experiments software, oil (Lauroglycol FCC), surfactant (Tween 20), and co-surfactant (Propylene glycol) were optimized for pre-isotropic compatibility and formulation development. RESULTS: The prepared SNEDDS exhibited non-Fickian mechanism of drug release, according to in vitro drug release kinetic data. The optimised formulation had uniform shape and nanosize with no physical incompatibilities between the selected excipients and the pure drug based on SEM, DSC and FT-IR. After six months of storage, remains stable, according to accelerated stability tests. CONCLUSIONS: In order to improve the therapeutic treatment of cardiovascular disease, the QbD approach presents an effective method to develop SNEDDS formulations of carvedilol with enhanced oral bioavailability and biopharmaceutical performance. KEYWORDS Pseudo-ternary phase diagram, Quality by design, SNEDDS, Hypertension, In vitro drug release, bioavailability, stability
  • Exploring application & recent advances of response surface methodology driven approach in drug design and nanotechnology
    Bikash Ranjan Jena, Aradhana Panigrahi, Surya Kanta Swain, Himansu Bhusan Samal, Pratap Kumar Patra
    Indian Journal of Microbiology Research, 2025
  • Biopolymers, hydrogel and their effect on drug development
    Smart Ways of Biomaterial Designing Synthesis and Characterization Prospects of Enhanced Application from Labs to Clinics, 2025
  • Polymeric nanoparticles used in biosensors
    Bikash Ranjan Jena, Rasmita Dash, Haragouri Mishra
    Materials and Components of Biosensors in Healthcare Volume 2, 2025
  • Recent Developments and Applications of 3D-Printing Technology in Pharmaceutical Drug Delivery Systems: A New Research Direction and Future Trends
    Surya Kanta Swain, Bikash Ranjan Jena, Rabinarayan Parhi
    Current Pharmaceutical Design, 2025
    The advent of 3D printing technology has emerged as a key technical revolution in recent years, enabling the development and production of innovative medication delivery methods in the pharmaceutical sector. The designs, concepts, techniques, key challenges, and potential benefits during 3D-printing technology are the key points discussed in this review. This technology primarily enables rapid, safe, and low-cost development of pharmaceutical formulations during the conventional and additive manufacturing processes. This phenomenon has wide-ranging implications in current as well as future medicinal developments. Advanced technologies such as Ink-Jet printing, drop-on-demand printing, Zip dose, Electrohydrodynamic Printing (Ejet) etc., are the current focus of the drug delivery systems for enhancing patient convenience and improving medication compliance. The current and future applications of various software, such as CAD software, and regulatory aspects in 3D and 4D printing technology are discussed briefly in this article. With respect to the prospective trajectory of 3D and 4D printing, it is probable that the newly developed methods will be predominantly utilized in pharmacies and hospitals to accommodate the unique requirements of individuals or niche groups. As a result, it is imperative that these technologies continue to advance and be improved in comparison to 2D printing in order to surmount the aforementioned regulatory and technical obstacles, render them applicable to a vast array of drug delivery systems, and increase their acceptability among patients of every generation.
  • Electrospun chitosan as a drug delivery system
    Rabinarayan Parhi, Bikash Ranjan Jena, Bhisma Narayan Ratha, Suryakanta Swain
    Electrospun Biomaterials for Tissue Engineering and Drug Delivery Applications, 2025
  • Self-emulsifying Drug Delivery Systems: Concept to Applications, Regulatory Issues, Recent Patents, Current Challenges and Future Directions
    Rajib Lochan Maharana, Suryakanta Swain, Santosh Kumar Mahapatra, Bikash Ranjan Jena
    Current Pharmaceutical Biotechnology, 2025
    Self-emulsifying drug delivery systems (SEDDS) can increase the solubility and bioavailability of poorly soluble drugs. The inability of 35% to 40% of new pharmaceuticals to dissolve in water presents a serious challenge for the pharmaceutical industry. As a result, there must be dosage proportionality, considerable intra- and inter-subject variability, poor solubility, and limited lung bioavailability. As a result, it is critical that drugs intended for oral administration be highly soluble. This can be improved through a variety of means, including salt generation and the facilitation of solid and complicated dispersion. Surfactants, co-surfactants, and cosolvents may occasionally be found in SEDDS or isotropic blends. Lipophilic drugs, whose absorption is limited by their dissolution rate, have been used to demonstrate the effectiveness of various formulations and techniques. These particles can form microemulsions and suitable oilin- water emulsions with minimal agitation and dilution by the water phase as they pass through the gastrointestinal tract. This study summarises the numerous advances, biopharmaceutical components, variations, production techniques, characterisation approaches, limitations, and opportunities for SEDDS. With this context in mind, this review compiles a current account of biopharmaceutical advancements, such as the application of quality by design (QbD) methodologies to optimise drug formulations in different excipients with controllable ratios, the presence of regulatory roadblocks to progress, and the future consequences of SEDDS, encompassing composition, evaluation, diverse dosage forms, and innovative techniques for in-vitro converting liquid SEDDS to solid forms.
  • Emerging Applications of Medical Nanorobots in Health Care: Current Trends and Future Prospects
    Surya Kanta Swain, Prafulla Kumar Sahu, Bikash Ranjan Jena, Biswajeet Acharya
    Current Molecular Medicine, 2025
  • Nanomedicines for the management of atherosclerosis
    Rabinarayan Parhi, Bikash Ranjan Jena, Aradhana Panigrahi, Suryakanta Swain
    Nanobiomaterials and Nanomedicines for Metabolic Disorders, 2025
  • Computational Modelling of Pharmaceutical Die Filling Processes
    Naseeb Basha Shaik, Roja Rani Budha, Bikash Rajan Jena, Rajasekhar Reddy Alavala, S. N. Koteswara Rao G.
    Applications of Computational Tools in Drug Design and Development, 2025
  • Central composite design enabled formulation development, optimization, and characterization of bosutinib monohydrate loaded lipid nanoparticles: Cytotoxicity studies
    Dhananjay Panigrahi, Surya Kanta Swain, Bikash Ranjan Jena, Prasanna Parida, Pratap Kumar Sahu
    Journal of Applied Pharmaceutical Science, 2025
  • Liquisolid Technique for Solubility Enhancement of Poorly Soluble Drug - A Brief Review
    Amaresh Prusty, Bikash Ranjan Jena, Vivek Barik, Piyali Khamkat, Bhakti Bhusan Barik
    Current Drug Discovery Technologies, 2025
  • Biodegradable Polymer-based Nanoparticles: A Breakthrough in Oral Protein Drug Delivery
    Prasanna Parida, Amiya Kumar Prusty, Bikash Ranjan Jena, Diptimayee Jena, Chinmaya Sahoo
    Nanoscience and Nanotechnology Asia, 2025
  • Ionic gelation technique using biodegradable polymer for stabilized and sustained oral delivery of nano protein
    Prasanna Parida, Amiya Kumar Prusty, Chinmaya Sahoo, Sujit Dash, Bikash Ranjan Jena, et al.
    Advancement in Animal Handling and Generative AI for Pre Clinical Studies Animal Handling and Generative AI for Pre Clinical Studies, 2025
  • Envisioning Clinical Management of Breast Cancer: a Comprehensive Review
    Shubhashree Das, Gurudutta Pattnaik, Sovan Pattanaik, Bikash Ranjan Jena, Bhabani Sankar Satapathy, et al.
    Current Drug Discovery Technologies, 2025
  • Overcoming hurdles in oral protein and peptide drug delivery: Strategies for future prospective
    Prasanna Parida, Amiya Kumar Prusty, Rajat Kumar Prusty, Bikash Ranjan Jena, Debabrata Panda, et al.
    Advancement in Animal Handling and Generative AI for Pre Clinical Studies Animal Handling and Generative AI for Pre Clinical Studies, 2025
  • Development of in-situ ocular gel containing topiramate to understand its effect in intraocular pressure
    Biswajeet Puhan, Aradhana Panigrahi, Guptanjali Sahu, Yashwant Giri, Bikash Ranjan Jena, et al.
    Advancement in Animal Handling and Generative AI for Pre Clinical Studies Animal Handling and Generative AI for Pre Clinical Studies, 2025
  • IONPs as strategic nanotools for cancer therapy: Concise updates on facile synthetic methods and stabilization
    Jnanranjan Panda, Sagar Rout, Gurudutta Pattnaik, Himansu Bhusan Samal, Bikash Ranjan Jena, et al.
    Advancement in Animal Handling and Generative AI for Pre Clinical Studies Animal Handling and Generative AI for Pre Clinical Studies, 2025
  • COVID-19: Immergence, molecular mechanism of transmission and pathogenesis
    Chinmaya Chidananda Behera, Sagar Mishra, Biswajit Mishra, Gurudutta Pattnaik, Bikash Ranjan Jena, et al.
    Advancement in Animal Handling and Generative AI for Pre Clinical Studies Animal Handling and Generative AI for Pre Clinical Studies, 2025
  • Autonomous Robots: A Disruptive Technology in the Health Sector
    Creating Smart Healthcare with Blockchain and Advanced Digital Technology, 2025
  • Controlled Drug Delivery Systems: Advancements and Recent Patents
    Suryakanta Swain, Sambamoorthy Unnam, Bikash Ranjan Jena, Nagadeepthi Naidu, Akhila Tejaswini Pilla, et al.
    International Journal of Pharmaceutical Sciences and Nanotechnology, 2025
  • Development of sophisticated RP-HPLC approach for quantifying lornoxicam in API and pharmaceutical formulation
    Biswa Mohan Sahoo, Chandan Kumar Brahma, Bikash Ranjan Jena, Kirtimaya Mishra, Debabrata Panda, et al.
    Advancement in Animal Handling and Generative AI for Pre Clinical Studies Animal Handling and Generative AI for Pre Clinical Studies, 2025

RECENT SCHOLAR PUBLICATIONS

  • Nanomedicines for the management of atherosclerosis
    R Parhi, BR Jena, A Panigrahi, S Swain
    Nanobiomaterials and Nanomedicines for Metabolic Disorders, 515-551 , 2026
    2026
  • Quality by Design Optimization of Telmisartan-loaded Self-nanoemulsifying Drug Delivery Systems
    RL Maharana, S Swain, SK Mahapatra, BR Jena
    Current Nanomedicine 16 (1), 95-114 , 2026
    2026
  • Topical nanoparticles for the treatment of skin cancer: Present Concerns and Challenges
    P Nayak, SK Swain, IJ Das, SS Swain, BR Jena, HB Samal
    Journal of Drug Delivery Science and Technology, 107566 , 2025
    2025
    Citations: 2
  • Overcoming hurdles in oral protein and peptide drug delivery: Strategies for future prospective
    P Parida, AK Prusty, RK Prusty, BR Jena, D Panda, S Das
    Advancement in Animal Handling and Generative AI for Pre-clinical Studies, 28-41 , 2025
    2025
    Citations: 1
  • Development of in-situ ocular gel containing topiramate to understand its effect in intraocular pressure
    B Puhan, A Panigrahi, G Sahu, Y Giri, BR Jena, G Pattnaik
    Advancement in Animal Handling and Generative AI for Pre-clinical Studies … , 2025
    2025
  • Development of sophisticated RP-HPLC approach for quantifying lornoxicam in API and pharmaceutical formulation
    BM Sahoo, CK Brahma, BR Jena, K Mishra, D Panda, SN Tripathy, ...
    Advancement in Animal Handling and Generative AI for Pre-clinical Studies … , 2025
    2025
  • IONPs as strategic nanotools for cancer therapy: Concise updates on facile synthetic methods and stabilization
    J Panda, S Rout, G Pattnaik, HB Samal, BR Jena, BS Satapathy
    Advancement in Animal Handling and Generative AI for Pre-clinical Studies … , 2025
    2025
  • Ionic gelation technique using biodegradable polymer for stabilized and sustained oral delivery of nano protein
    P Parida, AK Prusty, C Sahoo, S Dash, BR Jena, K Mishra
    Advancement in Animal Handling and Generative AI for Pre-clinical Studies, 22-27 , 2025
    2025
    Citations: 1
  • COVID-19: Immergence, molecular mechanism of transmission and pathogenesis
    CC Behera, S Mishra, B Mishra, G Pattnaik, BR Jena, SK Mekap
    Advancement in Animal Handling and Generative AI for Pre-clinical Studies … , 2025
    2025
  • Exploring the In-Vitro Antibacterial and Anti Tubercular Activity of Lamotrigine through Repurposing Approach
    N Pedamallu, MB Sitty, BL Raghunandhan, V Ramya, B Tripura, BR Jena
    International symposium on Sustainable Drug Design and Nanoparticle … , 2025
    2025
  • Biodegradable Polymer-based Nanoparticles: A Breakthrough in Oral Protein Drug Delivery
    P Parida, AK Prusty, BR Jena, D Jena, C Sahoo
    Nanoscience & Nanotechnology-Asia 15 (4), E22106812388555 , 2025
    2025
    Citations: 2
  • Liquisolid technique for solubility enhancement of poorly soluble drug-A brief review
    A Prusty, BR Jena, V Barik, P Khamkat, BB Barik
    Current Drug Discovery Technologies 22 (4), E15701638318659 , 2025
    2025
    Citations: 3
  • Development and Characterization of Ketoconazole-Loaded Nail Lacquer for the Topical Treatment of Onychomycosis.
    PT Pradhan, A Panigrahi, J Ray, RS Dash, G Pattnaik, A Sahu, BR Jena, ...
    Journal of Young Pharmacists 17 (3) , 2025
    2025
  • Central composite design enabled formulation development, optimization, and characterization of bosutinib monohydrate loaded lipid nanoparticles: Cytotoxicity studies
    D Panigrahi, SK Swain, BR Jena, P Parida, PK Sahu
    Journal of Applied Pharmaceutical Science 15 (6), 137-155 , 2025
    2025
    Citations: 1
  • Biopolymers, Hydrogel and Their Effect on Drug Development
    BR Jena, BN Ratha, G Pattnaik, NJ Kothakota, B Puhan, SS Islam, ...
    Smart Ways of Biomaterial Designing Synthesis and Characterization, 152-170 , 2025
    2025
  • Envisioning Clinical Management of Breast Cancer: a Comprehensive Review
    S Das, G Pattnaik, S Pattanaik, BR Jena, BS Satapathy, A Pradhan
    Current Drug Discovery Technologies 22 (2), E290424229495 , 2025
    2025
    Citations: 2
  • Controlled Drug Delivery Systems: Advancements and Recent Patents
    S Swain, S Unnam, BR Jena, N Naidu, AT Pilla, H Chunduru, ...
    International Journal of Pharmaceutical Sciences and Nanotechnology (IJPSN … , 2025
    2025
    Citations: 1
  • Autonomous Robots: A Disruptive Technology in the Health Sector
    BR Jena, GSNK Rao, NJ Kothakota, RR Budha, L Srinivas, J Rajkumar, ...
    Creating Smart Healthcare with Blockchain and Advanced Digital Technology … , 2025
    2025
    Citations: 4
  • Self-emulsifying Drug Delivery Systems: Concept to Applications, Regulatory Issues, Recent Patents, Current Challenges and Future Directions
    RL Maharana, S Swain, SK Mahapatra, BR Jena
    Current Pharmaceutical Biotechnology 26 (3), 341-364 , 2025
    2025
    Citations: 7
  • Exploring application & recent advances of response surface methodology driven approach in drug design and nanotechnology
    A Panigrahi, BR Jena, SK Swain, HB Samal, PK Patra
    2025

MOST CITED SCHOLAR PUBLICATIONS

  • Mucoadhesive Multiparticulate Drug Delivery Systems: An ExtensiveReview of Patents
    S Komati, S Swain, ME Bhanoji Rao, BR Jena, V Dasi
    Advanced Pharmaceutical Bulletin 9 (4), 521-538 , 2019
    2019
    Citations: 58
  • Quality by design: concept to applications
    S Swain, R Parhi, BR Jena, SM Babu
    Current drug discovery technologies 16 (3), 240-250 , 2019
    2019
    Citations: 55
  • QbD-based design and characterization of mucoadhesive microspheres of quetiapine fumarate with improved oral bioavailability and brain biodistribution potential
    S Komati, S Swain, MEB Rao, BR Jena, S Unnam, V Dasi
    Bulletin of Faculty of Pharmacy, Cairo University 56 (2), 129-145 , 2018
    2018
    Citations: 36
  • Qbd-Based Formulation Optimization and Characterization Of Polymeric Nanoparticles of Cinacalcet Hydrochloride with Improved Biopharmaceutical Attributes
    D Ghose, CN Patro, BVVR Kumar, S Swain, BR Jena, D Punam Swain
    Turkish Journal of Pharmaceutical Sciences, DOI:10.4274/tjps.galenos.2020.08522 , 2020
    2020
    Citations: 33
  • Stem extract of Tabebuia chrysantha induces apoptosis by targeting sEGFR in Ehrlich Ascites Carcinoma
    SP Panda, UP Panigrahy, S Panda, BR Jena
    Journal of ethnopharmacology 235, 219-226 , 2019
    2019
    Citations: 28
  • A trimethoxy flavonoid isolated from stem extract of Tabebuia chrysantha suppresses angiogenesis in angiosarcoma
    SP Panda, UP Panigrahy, D Prasanth, US Gorla, C Guntupalli, DP Panda, ...
    Journal of Pharmacy and Pharmacology 72 (7), 990-999 , 2020
    2020
    Citations: 23
  • Applications of QbD-based software’s in Analytical Research and Development
    Bikash Ranjan Jena*, Siva Prasad Panda, Kulandaivelu Umasankar, Suryakanta ...
    Current Pharmaceutical Analysis 16 (1) , 2020
    2020
    Citations: 18
  • Application of Quality by Design Paradigms for Development of Solid Dosage Forms
    S Swain, BR Jena, D Madugula, S Beg
    Pharmaceutical Quality by Design, 109-130 , 2019
    2019
    Citations: 18
  • AQbD Driven Development of a RP-HPLC Method for the Quantitation of Abiraterone acetate for Its Pharmaceutical Formulations in presence of Degradants
    BR Jena, S Panda, U Kulandaivelu, AR Reddy, K Rao G.S.N, S Swain, ...
    Turkish Journal of Pharmaceutical Sciences, DOI:0.4274/tjps.galenos.2021.74150 , 2021
    2021
    Citations: 16
  • Recent Developments and Applications of 3D-Printing Technology in Pharmaceutical Drug Delivery Systems: A New Research Direction and Future Trends
    SK Swain, BR Jena, R Parhi
    Current Pharmaceutical Design 31 (1), 2-25 , 2025
    2025
    Citations: 13
  • Formulation development, optimization and characterization of mucoadhesive minitablets of cefuroxime axetil: in vitro, ex vivo and in vivo pharmacokinetic evaluation
    J Panda, MEB Rao, S Swain, CN Patra, BR Jena
    Beni-Suef University Journal of Basic and Applied Sciences 11 (1), 123 , 2022
    2022
    Citations: 13
  • UPLC Analytical Method Development and Validation for the Simultaneous Estimation of Paracetamol and Caffeine Capsules Dosages Form
    BR Jena, SM Babu, DP Pradhan, S Swain
    Pharm Regul Aff 6 (186), 2-9 , 2017
    2017
    Citations: 12
  • Overexpressed CYP450 mediated apoptosis evaluates cytotoxicity and teratotoxicity of Cucumis callosus
    SP Panda, BR Jena, G Kalyani, UP Panigrahy
    Oriental Pharmacy and Experimental Medicine, 1-11 , 2018
    2018
    Citations: 10
  • Advancement and Applications of Platelet-inspired Nanoparticles: A Paradigm for Cancer Targeting
    D Ghose, S Swain, CN Patra, BR Jena, MEB Rao
    Current Pharmaceutical Biotechnology 24 (2), 213-237 , 2023
    2023
    Citations: 9
  • Current Advancements on Oral Protein and Peptide Drug Delivery Approaches to Bioavailability: Extensive Review on Patents
    P Parida, AK Prusty, SK Patro, BR Jena
    Recent Advances in Drug Delivery and Formulation 18 (4), 227-246 , 2024
    2024
    Citations: 8
  • Formulation Development, Statistical Optimization and Charac-terization of the Self-Microemulsifying Drug Delivery System (SMEDDS) of Irbesartan
    Swain S, Beg S,Sahu P K,Jena BR, SM Babu
    Nanoscience & Nanotechnology-Asia 8 , 2018
    2018
    Citations: 8
  • Self-emulsifying Drug Delivery Systems: Concept to Applications, Regulatory Issues, Recent Patents, Current Challenges and Future Directions
    RL Maharana, S Swain, SK Mahapatra, BR Jena
    Current Pharmaceutical Biotechnology 26 (3), 341-364 , 2025
    2025
    Citations: 7
  • New Validated UV Spectrophotometric Method for the Quantification of Bisoprolol Fumarate in its Pharmaceutical Dosage Form
    SN Tripathy, S Swain, BR Jena, A Sahu
    Acta Scientific Pharmaceutical Sciences (ISSN: 2581-5423) 7 (2) , 2023
    2023
    Citations: 7
  • Cleaning validation in analytical development: Current challenges and future prospectives
    BR Jena, S Swain, DP Pradhan, D Ghose
    Int J Pharm Chem Anal 7 (3), 113-118 , 2020
    2020
    Citations: 7
  • Emerging Applications of Medical Nanorobots in Health Care: Current Trends and Future Prospects
    SK Swain, PK Sahu, BR Jena, B Acharya
    Current Molecular Medicine , 2024
    2024
    Citations: 6

RESEARCH OUTPUTS (PATENTS, SOFTWARE, PUBLICATIONS, PRODUCTS)

Expertise in Analytical Research and Development and Method Validations using statistical Multivariate analysis and Design of Experiments paradigim.
Expertise in QbD based softwares like Design Expert, Minitab, MatLab etc.
Sound knowledge of Analytical Quality by Design, Chemometrics, Various Statistical softwares and its immplementation
Handling of HPLC Instrumental softwares like Waters Empower 2, Shimadzu LC solution, n2000,
UV softwares like Win 5 and 6.2 etc.

Industry, Institute, or Organisation Collaboration

Worked at Analytical Research and Development, at Medreich Limited, Bengaluru, Karnataka.

INDUSTRY EXPERIENCE

Worked at Analytical Research and Development (A R & D), at Medreich Limited, Bengaluru, Karnataka during Dec 2011- Sept 2012.
I have worked in Celogen Pharma Pvt Ltd, Corporate Head office Navi Mumbai as Regulatory Affairs Executive from december 2012 to Dec 2013